In summary, our study found that ITLN1, regulated by IFNγ-IRF1 axis, suppresses HCC proliferation by constitutively activating ERK1/2 signaling and holds promise as a prospective prognostic indicator and a plausible therapeutic target for HCC. This evidence concerns the gene ITLN1 and hepatocellular carcinoma.